The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...
Index was cofounded in late 2023 by Simon Kubica, who spent five years at Atlassian and Christian Iacullo, who spent similar ...
The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...
Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.
Fundraising in the private-markets business can be tough. Wining and dining big investors for each new vehicle creates an endless treadmill. Worse, the typical closed-end fund structure ignores ...
When unions push too hard on leadership decisions, it doesn’t always end well. And perhaps it’s best governments stay out of ...
A case study looking at Amplitude’s purchase of Command AI last year, and the new product they developed together.
This moated ASX company's shares are in a prolonged slump. I quizzed our analyst Angus Hewitt on its management, the ...
Rising health insurance exhange enrollment, paired with stricter Medicare marketing rules, attracted rogue actors to the ...
Facing extinction, Sezzle chopped costs and hit on a strategy for making money from the heaviest users. The stock market noticed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback